Natera Reports Second Quarter 2023 Financial Results

Natera Reports Second Quarter 2023

AUSTIN, Texas, August 3, 2023 /PRNewswire/ - Natera, Inc.

(NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial

results for the second quarter ended June 30, 2023.

Recent Strategic and Financial Highlights

"We had another strong quarter in

which we served over 600,000 patients, delivered significant year-over-year growth in volumes and revenues, drove improvements in

gross margin and reduced our quarterly cash burn," said Steve Chapman, Natera's Chief Executive Officer. "With

this excellent performance, we are raising our annual revenue guidance and believe we are well-positioned to meet our financial

goals for the year. Looking ahead, we have a robust clinical pipeline, particularly in oncology, that we believe will further

differentiate our products and change the standard of care for millions of patients."

Second Quarter Ended June 30, 2023 Financial Results

Total revenues were $261.4 million in the second

quarter of 2023, compared to $198.2 million for the second quarter of 2022, an increase of 31.9%. Product revenues were $258.3 million

in the second quarter of 2023, compared to $194.6 million in the second quarter of 2022, an increase of 32.7%. The growth in product revenues

was driven by an increase in test volumes compared to the second quarter of 2022.

Natera processed approximately 617,200 tests in

the second quarter of 2023, including approximately 599,000 tests accessioned in its laboratory. This compares to approximately 499,900

tests processed in the second quarter of 2022, including approximately 484,000 tests accessioned in its laboratory, an increase of 23.5%.

In the three months ended June 30, 2023,

Natera recognized revenue on approximately 594,900 tests for which results were reported to customers in the period (tests reported),

including approximately 578,200 tests reported from its laboratory, compared to approximately 461,300 tests reported, including approximately

446,400 tests reported from its laboratory, in the second quarter of 2022, an increase of 29.0% for the quarter.

Gross profit* for the three months ended June 30,

2023 and June 30, 2022 was $118.3 million and $89.0 million, respectively, representing a gross margin of 45.2% and 44.9%.

Natera had higher margins in the second quarter of 2023 compared to the second quarter of 2022 primarily as a result of increased revenues

and continuous progress in cost of goods sold associated with tests processed.

Total operating expenses, representing research

and development expenses and selling, general and administrative expenses, for the second quarter of 2023 were $230.7 million, compared

to $232.0 million in the same period of the prior year, a decrease of 0.6%. The decrease was primarily driven by a reduction

in payroll and related expenses due to headcount reduction; as well as reduction of in-process research and development expenses.

Loss from operations for the second quarter of 2023 was $112.4 million, compared to $143.1 million for the same period

The Company reported a net loss for the second

quarter of 2023 of $110.8 million, or ($0.97) per diluted share, compared to a net loss of $145.2 million, or ($1.50) per diluted share,

for the same period in 2022. Weighted average shares outstanding were approximately 113.7 million in the second quarter of 2023, compared

to 96.6 million in the second quarter of the prior year.

As of June 30, 2023, Natera held approximately

$735.9 million in cash, cash equivalents, short-term investments and restricted cash, compared to $898.4 million as of December 31,

2022. As of June 30, 2023, Natera had a total outstanding debt balance of $362.7 million, comprised of $80.4 million including accrued

interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 121 basis points and a net carrying amount

of $282.3 million under its seven-year convertible senior notes issued in April 2020. The gross principal balance outstanding for

the convertible senior notes was $287.5 million as of June 30, 2023.

Natera is raising its expectations for 2023

total revenue from $995 million to $1.015 billion to a new range of $1.015 billion to $1.035 billion. The Company expects 2023 gross

margin to be approximately 41% to 44% of revenues; selling, general and administrative costs to be approximately $540 million to $580 million;

research and development costs to be approximately $325 million to $345 million; and net cash consumption to be approximately $300

million to $325 million**.

* Gross profit is calculated as GAAP total revenues

less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues.

** Cash consumption is calculated as the sum of

GAAP net cash used by operating activities (estimated for 2023 to be approximately $250 million to $275 million) and GAAP net purchases

of property and equipment (estimated for 2023 to be approximately $50 million).

is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized

genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help

lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high

accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments

(CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Conference Call Information

Forward-Looking Statements

This press release contains forward-looking statements

under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including

the company's financial guidance for fiscal 2022, its ability to continue to increase its revenues, its product development plans

and its ability to maintain and grow its business operations in light of the COVID-19 pandemic, are forward-looking statements. Any forward-looking

statements contained in this press release are based upon Natera's current plans, estimates, and expectations, as of the date of

this release, and are not a representation that such plans, estimates, or expectations will be achieved.

These forward-looking statements are subject to

known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties

and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products

through our direct sales efforts or through our laboratory partners; we have incurred losses since our inception and we anticipate that

we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates

of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing

or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions

that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our

financial resources; we may need to raise additional capital to support our business plans, which may not be available when necessary

or on favorable terms; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as

expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not

be compelling to professional societies or payors as supporting the use of our tests, particularly for microdeletions screening, or may

not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified

laboratories becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of

suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements

or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer;

the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or

professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and

reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party

payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors;

if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket

clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, including

investigations, subpoenas, demands, disputes, litigation, requests for information and other regulatory or administrative actions or proceedings,

or resulting from either third party claims of intellectual property infringement or asserting infringement by third parties of our technology,

is costly, may result in substantial business and financial penalties, may be time-consuming and could limit our ability to commercialize

our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand;

and we cannot guarantee that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding

the conversion of our outstanding convertible notes.

Additional risks and uncertainties that could

affect our financial results are included under the captions, "Risk Factors" and "Management's Discussion and

Analysis of Financial Condition and Results of Operations" in our most recent filings on Forms 10-K and 10-Q and in other filings

that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations

section and on the SEC's website at www.sec.gov.